Shah Capital blasts Novavax annual meeting results

Novavax is facing growing pressure from shareholders after the results of its 2026 Annual General Meeting revealed unusually strong opposition to several key proposals, despite all resolutions ultimately passing. The vote has intensified debate over the biotechnology company's leadership, corporate governance, and long-term strategy as it works toward future growth through its vaccine pipeline.

The strongest backlash centered on executive compensation, with a significant number of shareholders voting against the company's pay proposals. At the same time, roughly **38% to 41%** of votes cast opposed the re-election of each of the three Class I directors, signaling widespread dissatisfaction with the company's board and management performance.

The outcome prompted an immediate response from **Shah Capital**, Novavax's largest shareholder and a long-time activist investor. While acknowledging that the proposals were approved, the investment firm argued that the voting results represented one of the clearest signs yet of declining shareholder confidence in the company's leadership.

Shah Capital founder and Chief Investment Officer **Himanshu Shah** described the vote as a "wake-up call" for Novavax's management, saying investors are increasingly frustrated with what he characterized as weak execution, excessive administrative spending, high consulting costs, and years of shareholder value destruction.

According to Shah Capital, the voting results reinforce concerns the firm has repeatedly raised about the company's direction. The investor continues to advocate for a smaller and more accountable board, lower operating costs, a more disciplined business strategy, and an immediate share repurchase program, arguing that Novavax's stock remains significantly undervalued.

The company, however, noted that its proposals received support from leading independent proxy advisory firms before the meeting. Management also continues to emphasize its long-term strategy focused on expanding its vaccine portfolio and improving financial performance.

Novavax remains one of the biotechnology industry's leading developers of recombinant protein-based vaccines and adjuvant technologies. Following the commercial challenges experienced after the COVID-19 pandemic, the company is increasingly relying on the successful development and commercialization of its next-generation **COVID-19 and influenza combination vaccine**, which executives believe could become a major driver of future revenue and profitability.

The shareholder vote comes at a critical time for the company as investors closely monitor its financial performance, product pipeline, regulatory progress, and ability to restore sustainable growth. Market analysts say continued pressure from activist investors could influence future governance decisions if operational performance does not improve.

With shareholder frustration now publicly reflected in the AGM voting results, Novavax faces mounting expectations to demonstrate stronger execution, improve cost discipline, and rebuild investor confidence while advancing its vaccine development programs in an increasingly competitive biotechnology market.